ArticleRSC advances2021
Biologically guided isolation and ADMET profile of new factor Xa inhibitors from
Article in RSC advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Chemical Profiling and Antimicrobial Activity of the Leaf Essential Oil ofInternational journal of molecular sciences · 2026Article
- Molecular mechanisms of phytoconstituents from selected Egyptian plants against non-small cell lung cancer using integrated in vitro network pharmacology and molecular docking approach.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Bioassay-guided isolation of sesamin and fargesin from the hydroalcoholic stem extract ofFrontiers in pharmacology · 2025Article
- Metabolic profiling of milk thistle different organs using UPLC-TQD-MS/MS coupled to multivariate analysis in relation to their selective antiviral potential.BMC complementary medicine and therapies · 2024Article
- Natural Phenolic Compounds with Antithrombotic and Antiplatelet Effects: A Drug-likeness Approach.Current medicinal chemistry · 2024Review
- Computational biology and in vitro studies for anticipating cancer-related molecular targets of sweet wormwood (Artemisia annua).BMC complementary medicine and therapies · 2023Article
- Review on the Diverse Biological Effects of Glabridin.Drug design, development and therapy · 2023Review
- An exhaustive comprehension of the role of herbal medicines in Pre- and Post-COVID manifestations.Journal of ethnopharmacology · 2022Review
- Revisiting liquorice (Phytomedicine plus : international journal of phytotherapy and phytopharmacology · 2022Review
- Novel 1,2,3-Triazole Erlotinib Derivatives as Potent IDO1 Inhibitors: Design, Drug-Target Interactions Prediction, Synthesis, Biological Evaluation, Molecular Docking and ADME Properties Studies.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Selective factor Xa inhibitors effectively block coagulation cascade with a broader therapeutic window than multitargeted anticoagulants. They have evolved as a crucial part of prevention and treatment of thromboembolic diseases and in therapeutic protocols involved in many clinical trials in coronavirus disease 2019 (COVID-19) patients. Biologically-guided isolation of specific FXa inhibitors from licorice (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.